Combination Therapeutic Agents for the Treatment of Pancreatic Cancer

A combination of a MEK inhibitor and a multitargeted agent targeting PDGFRα, S6, and STAT3 addresses drug resistance in pancreatic cancer by blocking key signaling pathways, achieving tumor regression and inhibiting metastasis.

JP7579636B2Active Publication Date: 2024-11-08GENENTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2019510651
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-08-23
Filing Date
2017-08-22
Publication Date
2024-11-08
Estimated Expiration
2037-08-22

AI Technical Summary

Technical Problem

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is highly malignant and resistant to current treatments due to KRAS mutation-driven activation of the MAPK signaling pathway, leading to rapid development of drug resistance through compensatory mechanisms, limiting the efficacy of MEK inhibitors.

Method used

A combination therapy using a MEK inhibitor and a multitargeted agent that targets PDGFRα, S6, and STAT3 to block signaling pathways and prevent compensatory feedback loops, thereby inhibiting tumor growth and metastasis.

Benefits of technology

The combination therapy effectively inhibits pancreatic cancer cell proliferation and metastasis by blocking PDGFRα and STAT3 activation, leading to tumor regression and reduced tumor-associated macrophage infiltration, even in drug-resistant tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579636000014
    Figure 0007579636000014
  • Figure 0007579636000015
    Figure 0007579636000015
  • Figure 0007579636000016
    Figure 0007579636000016
Patent Text Reader

Abstract

The problem described herein relates to a composition comprising a MEK inhibitor or its pharmaceutically acceptable salt and a multikinase inhibitor or its pharmaceutically acceptable salt that targets PDGFRα, S6, and STAT3, and the use of this composition in the treatment of pancreatic cancer.In another embodiment, the present invention discloses a method for treating pancreatic cancer by administering a MEK inhibitor or its pharmaceutically acceptable salt and a multikinase inhibitor or its pharmaceutically acceptable salt.In another embodiment, to treat pancreatic cancer, cobimetinib or its pharmaceutically acceptable salt and ponatinib or its pharmaceutically acceptable salt are administered in the form of a composition, or the combination is administered separately. [Selection diagram] Figure 20A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The subject matter described herein relates to the treatment of pancreatic cancer by combining a MEK inhibitor with a multi-targeted agent that targets RTK, S6, and JAK / STAT.

[0002] [Reference to sequence listing submitted as a text file via EFS-Web] An official copy of the Sequence Listing was submitted electronically via EFS-Web as an ASCII format Sequence Listing in a file named 501159SEQLIST.TXT, created on August 10, 2017, and having a size of 471 bytes, and is being submitted contemporaneously herewith. The Sequence Listing contained in this ASCII format document is a part of the present specification and is incorporated herein by reference in its entirety. [Background technology]

[0003] Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, and numerous therapeutic approaches have been investigated based on the results of drug responses from pancreatic cancer cells tested in culture models. The majority of PDAC tumors are caused by KRAS mutation-driven activation of MAPK signaling (Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 2008; 321(5897): 1801-6, Epub 2008 / 09 / 06, Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes, Nature, 2012; 491(7424): 399-405, Epub 2012 / 10 / 30, Cid-Arregui A, Juarez V, Perspectives in the treatment of pancreatic adenocarcinoma, World Journal of Gastroenterology, 2015;21(31):9297-316, Epub 2015 / 08 / 27), thereby highlighting MEK as an important candidate target for therapeutic intervention in PDAC patients. However, preclinical and clinical studies have revealed that MAPK pathway inhibition alone lacks efficacy, as resistance to MAPK inhibitors through various compensatory mechanisms can rapidly develop, thereby limiting the efficacy of the inhibitors and potentially leading to the development of drug-resistant tumors.(Baines AT,Xu D,Der CJ,Inhibition of Ras for cancer treatment:the search continues,Future Medicinal Chemistry,2011;3(14):1787-808,Epub 2011 / 10 / 19,McCubrey JA,Steelman LS,Chappell WH,Abrams SL,Franklin RA,Montalto G,Ras / Raf / MEK / ERK and PI3K / PTEN / Akt / mTOR cascade inhibitors:how mutations can result in therapy resistance and how to overcome resistance,Oncotarget,2012;3(10):1068-111,Epub 2012 / 10 / 23, Junttila MR,Devasthali V,Cheng JH,Castillo J,Metcalfe C,Clermont AC,Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer,Molecular Cancer Therapeutics,2015;14(1):40-7,Epub 2014 / 11 / 08).

[0004] A better understanding of the mechanisms underlying sensitivity and resistance to MEK inhibitors could identify inhibitors for use in combination with MEK inhibitors that are effective in targeting pancreatic cancer cells. Summary of the Invention

[0005] In one aspect, the subject matter described herein relates to a method of treating pancreatic cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of active agents, wherein the combination comprises a MEK inhibitor and a multikinase agent that targets PDGFRα, S6, and STAT3.

[0006] In another aspect, the subject matter described herein relates to a combination of a) a MEK inhibitor, or a pharma- ceutically acceptable salt thereof, and b) a multikinase inhibitor targeting PDGFRα, S6, and STAT3, or a pharma- ceutically acceptable salt thereof, for the treatment of pancreatic cancer.

[0007] In another aspect, the subject matter described herein relates to a pharmaceutical composition comprising an effective amount of a combination of a MEK inhibitor or a pharma- ceutical acceptable salt thereof and a multikinase agent that targets PDGFRα, S6, and STAT3, or a pharma- ceutical acceptable salt thereof, and a pharma- ceutical acceptable excipient, wherein said composition is for the treatment of pancreatic cancer.

[0008] In another aspect, the subject matter described herein relates to a kit for treating pancreatic cancer, comprising: a) a MEK inhibitor or a pharmaceutically acceptable salt thereof, and a multikinase inhibitor targeting PDGFRα, S6, and STAT3 or a pharmaceutically acceptable salt thereof, for treating pancreatic cancer; and b) a package insert or label indicating the treatment of pancreatic cancer.

[0009] These and other aspects are described more fully below. [Brief description of the drawings]

[0010] [Figure 1] Differential response to MEK inhibition by KP4 PDAC cells in 2D monolayer and 3D spheroid cultures. Small molecule inhibitor screening of KP4 cancer cells in 2D and 3D culture. [Diagram 2] FIG. 14 shows the differential response to MEK inhibition by KP4 PDAC cells in 2D monolayer and 3D spheroid cultures. Phosphokinase array layout with darkened positions of differentially activated proteins in panel C. [Diagram 3] Figure 2 shows the differential response to MEK inhibition by KP4 PDAC cells in 2D monolayer and 3D spheroid cultures. Phosphokinase arrays of KP4 cells in 2D and 3D. [Figure 4] Figure 1. Differential response to MEK inhibition by KP4 PDAC cells in 2D monolayer and 3D spheroid cultures. Protein kinase array by RT-PCR of KP4 cells cultured in 2D or 3D and treated with cobimetinib for 24 hours. Samples were normalized to DMSO-treated KP4 2D controls. [Diagram 5] Differential response to MEK inhibition by KP4 PDAC cells in 2D monolayer and 3D spheroid cultures. Luciferase reporter assay of KP4 cells cultured in 2D or 3D and treated with cobimetinib for 24 hours. Transcription factors with significant differences in fold change in luciferase activity are shown in red. [Figure 6A-B] We show that MEK inhibition induces activation of PDGFRα, S6, and STAT3. (Figure 6A) Immunoblot verifying activation of PDGFRα, S6, and STAT3 upon cobimetinib treatment in KP4 cells. (Figure 6B) Western blot verifying increase in p-STAT3 upon cobimetinib treatment in PDAC cell lines and KPP-GEMM-derived cell lines. [Figure 7] We show that MEK inhibition induces activation of PDGFRα, S6, and STAT3.IL-6 secretion levels were measured in 2D culture supernatants of PDAC cell lines treated with cobimetinib for 24 hours. [Figure 8] Figure 2 shows that MEK inhibition induces activation of PDGFRα, S6, and STAT3.CTG assay measuring the effect of Dox-induced STAT3 knockdown in combination with cobimetinib on the viability of KP4 and MIA-PACA2 cells. [Figure 9] Figure 2 shows that MEK inhibition induces activation of PDGFRα, S6, and STAT3. Western blot confirming efficient knockdown of STAT3 after 72 h treatment with Dox (1 μg / ml). [Figure 10]Showing that MEK inhibition induces activation of PDGFRα, S6, and STAT3 Quantification of the invasive potential of pancreatic cancer cells cultured in 2D and 3D in response to 10% FBS in a Matrigel invasion assay. [Figure 11] We show that inhibition of S6 and STAT3 in combination with cobimetinib enhances the killing of pancreatic cancer cells.The effect of the multi-RTK inhibitor ponatinib in combination with cobimetinib on the activation of signaling receptors and downstream targets was examined by Western blot. [Figure 12] We show that inhibition of S6 and STAT3 in combination with cobimetinib enhances pancreatic cancer cell killing. The effects of cobimetinib + / - ponatinib or JAK inhibitors on STAT3 activation and induction of cleaved PARP were examined by Western blot. [Figure 13] Showing that inhibition of S6 and STAT3 in combination with cobimetinib increases pancreatic cancer cell killing. PathScan Multiplex Western blot analysis of KP4 cells pretreated with cobimetinib + / - ponatinib in 2D and 3D culture. [Figure 14] We show that inhibition of S6 and STAT3 in combination with cobimetinib enhances pancreatic cancer cell killing.The effect of cobimetinib + / - ponatinib / S6 / PDGFRα inhibitors on S6 activation and induction of cleaved PARP was examined by Western blot. [Figure 15] We show that inhibition of S6 and STAT3 in combination with cobimetinib increases pancreatic cancer cell killing.The effect of the PDGFR inhibitor crenolanib in combination with cobimetinib and ruxolitinib on the viability of KP4 cells was measured using a CTG assay. [Figure 16] We show that inhibition of S6 and STAT3 in combination with cobimetinib increases pancreatic cancer cell killing.The synergy between cobimetinib and ponatinib was analyzed in pancreatic cancer cell lines using the Bliss analysis. [Figure 17]We show that inhibition of S6 and STAT3 in combination with cobimetinib increases pancreatic cancer cell killing.The synergy between cobimetinib and ponatinib was analyzed in pancreatic cancer cell lines using the Bliss analysis. [Figure 18] Showing that inhibition of S6 and STAT3 in combination with cobimetinib increases pancreatic cancer cell killing. Bliss analysis of synergy between cobimetinib and the S6 inhibitor rapamycin in KP4 cells. [Figure 19] Showing that inhibition of S6 and STAT3 in combination with cobimetinib increases pancreatic cancer cell killing. BLISS analysis of synergy between cobimetinib and GDC-0980 in KP4 cells. [Figure 20A-B] Inhibition of PDGFRα / S6 / STAT3 and MEK inhibits tumor growth and reduces serum PDGFα (Figure 20A).Tumor growth curves (mean ± SEM) of KP4 xenograft models treated with cobimetinib (5 mg / kg, PO, QD) and / or ponatinib (30 mg / kg, PO, QD) every 24 hours (n=10 for each cohort), (Figure 20B).Tumor growth curves (mean ± SEM) of KPP xenograft models treated as in (Figure 20A). [Figure 21] Figure 1 shows that inhibition of PDGFRα / S6 / STAT3 and MEK inhibits tumor growth and reduces serum PDGFα. Representative tumor sections from KP4 xenografts were stained for p-STAT3, p-Erk, and cleaved caspase 3 by IHC or co-stained with p-STAT3 and antibodies against F4 / 80 or p-PDGFRα by IF. Scale bars: 20 μm for IHC slides and 50 μm for IF slides. [Figure 22] Showing that inhibition of PDGFRα / S6 / STAT3 and MEK inhibits tumor growth and reduces serum PDGFα. Immunoblots validating activation of PDGFRα, S6, and STAT3 upon cobimetinib / ponatinib treatment of KP4 xenograft tumors. [Figure 23]Figure 1 shows that inhibition of PDGFRα / S6 / STAT3 and MEK inhibits tumor growth and reduces serum PDGFα. Luminex assay for growth factors and cytokines in plasma samples from KP4 xenografted mice. [Figure 24] 1 shows an analysis of p-Erk and p-STAT3 in pancreatic tumors and metastases from PDAC patient samples. Distribution of p-Erk and p-STAT3 positive samples at different stages of malignancy in primary tumors and metastases from 82 PDAC patients. [Diagram 25] Analysis of p-Erk and p-STAT3 in pancreatic tumors and metastases from PDAC patient samples. Representative primary tumor and liver sections stained for p-Erk and p-STAT3 in PDAC patient samples. Scale bar: 20 μm. [Figure 26] 4 shows analysis of p-Erk and p-STAT3 in pancreatic tumors and metastases from PDAC patient samples.Microarray analysis of PDGFR and IL-6R expression in PDAC patient tumor samples. [Figure 27A-B] We show that KP4-derived 3D spheroids with histopathological features of micrometastases exhibit differential sensitivity to small molecule inhibitors.KP4 cells were cultured for 3 days in RPMI medium containing 10% normal FBS (for 2D culture) or 10% pre-boiled FBS (for 3D culture), and IHC was performed on 2D cell pellets or 3D spheroids for Ki67, p-STAT3, and cleaved caspase-3. [Figure 28] We show that KP4-derived 3D spheroids with histopathological features of micrometastases display differential sensitivity to small molecule inhibitors. Spheroids formed using 10% pre-boiled FBS display a drug sensitivity profile similar to that seen with other conventional 3D culture methods. [Figure 29] Figure 1. KP4-derived 3D spheroids with histopathological features of micrometastases exhibit differential sensitivity to small molecule inhibitors. Cell viability and colony count assays of spheroids formed from different 3D culture methods. [Diagram 30]Figure 1. Cobimetinib / ponatinib co-treatment inhibits tumor growth and reduces tumor-associated macrophage infiltration. Representative tumor sections from KPP xenografts probed with p-Erk and p-STAT3 antibodies by IHC or co-stained with anti-p-STAT3 and anti-F4 / 80 by immunofluorescence. Scale bars: 20 μm for IHC slides and 50 μm for IF slides. [Fig. 31A-B] Figure 2. Cobimetinib / ponatinib co-treatment inhibits tumor growth and reduces tumor-associated macrophage infiltration. Body weight change in cobimetinib + / - ponatinib-treated mice in KP4 and KPP xenograft models. [Diagram 32] Figure 1. Luminex assay of growth factors in plasma samples from KP4 xenografted mice. [Diagram 33] Showing that cobimetinib / ponatinib cotreatment inhibits tumor growth and reduces tumor-associated macrophage infiltration. Immunoblots validating activation of PDGFRα, S6, and STAT3 upon cobimetinib / ponatinib treatment of KPP xenograft tumors.

[0011] Data in Figures 6-23 are expressed as mean ± SEM. *P<0.05, Student's t test. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human diseases and remains largely refractory to available drug therapies. In most pancreatic cancers, the KRAS-driven MEK pathway is mutationally activated and is a key target for therapeutics. However, insufficient targeting of known oncogenic drivers and activation of compensatory feedback loops, as well as failure to prevent metastatic spread, contribute to the poor prognosis of this disease.

[0013] Activation of transmembrane receptor tyrosine kinases (RTKs) triggers numerous biochemical cascades that result in the regulation of cell fate. This activation is regulated by molecules in the extracellular environment, mainly growth factors, extracellular matrix (ECM) proteins, and adhesion molecules present on the surface of neighboring cells. The cellular response to these signals occurs when the molecules bind to specific receptors present on the cell's surface. Many growth factors (GFs) bind to and activate transmembrane glycoproteins of the receptor tyrosine kinase (RTK) family.

[0014] RTKs contain an extracellular ligand-binding domain, a single transmembrane domain, and a tyrosine kinase domain, as well as an intracellular component that contains several regulatory tyrosines. RTKs can phosphorylate and activate cytoplasmic STAT family transcription factors. These activated STATs translocate to the nucleus. Once in the nucleus, STATs enhance the transcription of genes involved in cell proliferation.

[0015] Platelet-derived growth factor receptors (PDGFRs) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. The PDGFRα and PDGFRβ isoforms are factors that regulate cell proliferation, cell differentiation, cell growth and development. Upon binding, the two isoforms dimerize and activate kinase activity and phosphorylation of PDGFR. Tyrosine phosphorylation sites on growth factor receptors control the activity level of kinases and are often binding sites for downstream signaling that are also substrates for kinases. This signaling cascade, which includes downstream signaling molecules such as S6 ribosomal protein, is involved in many diseases, including cancer.

[0016] As described herein, by using two-dimensional monolayer and three-dimensional spheroid culture systems, it was found that combination treatment with MEK inhibitors or pharma- ceutically acceptable salts thereof and multitargeting agents or pharma- ceutically acceptable salts thereof targeting PDGFRα, S6, and STAT3 was effective in targeting pancreatic cancer cells in both monolayer and spheroid. Without being bound by theory, this combination can effectively block signaling through PDGFRα and MEK kinases while also preventing the activation of STAT3- and S6-mediated compensatory feedback loops in cancer cells. Furthermore, as described herein, using xenograft models, co-treatment with MEK inhibitors and ponatinib caused tumor regression and simultaneously inhibited myeloid populations that promote PDAC tumor progression by targeting tumor-associated macrophages in the pancreatic tumor microenvironment, thereby promoting tumor regression through a dual mechanism. PDAC patient samples revealed increased STAT3 activation in tumors and Erk activation in liver metastases, suggesting that STAT3 and Erk are key drivers in PDAC tumors and liver metastases, respectively. As described herein, these results suggest a combination drug therapy strategy for the effective treatment of pancreatic cancer. Moreover, active agents administered alone may not be effective against pancreatic cancer.

[0017] Survival pathways identified as PDGFRβ, MEK, S6, and STAT3 have been reported to be involved in tumorigenesis and metastasis in various cancer models (Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, Stat3 / Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer, Cancer Cell, 2011;19(4):456-69, Epub 2011 / 04 / 13, Yen TW, Aardal NP, Bronner MP, Thorning DR, Savard CE, Lee SP, Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas, Surgery, 2002;131(2):129-34, Epub 2002 / 02 / 21, Weissmueller S, Manchado E,Saborowski M,Morris JPt,Wagenblast E,Davis CA,et al.Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling,Cell,2014;157(2):382-94,Epub 2014 / 04 / 15,Corcoran RB,Rothenberg SM,Hata AN,Faber AC,Piris A,Nazarian RM,TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma,Science Translational Medicine,2013;5(196):196ra98,Epub 2013 / 08 / 02、Corcoran RB,Cheng KA,Hata AN,Faber AC,Ebi H,Coffee EM,Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models,Cancer Cell,2013;23(1):121-8,Epub 2012 / 12 / 19、Deng J,Liu Y,Lee H,Herrmann A,Zhang W,Zhang C,S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites,Cancer Cell,2012;21(5):642-54,Epub 2012 / 05 / 26、Corcoran RB,Contino G,Deshpande V,Tzatsos A,Conrad C,Benes CH,STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis,Cancer Research,2011;71(14):5020-9, Epub 2011 / 05 / 19), MEK inhibition in primary pancreatic tumors has now been found to induce activation of alternative signaling pathways through PDGFRα, S6, and STAT3, which contribute to resistance to single-agent MEK inhibition. Notably, individual agents that individually showed no effect on cell viability have been shown to inhibit cell proliferation in both 2D and 3D cultures when combined. Thus, inhibition of PDGFRα, S6, and STAT3 activation in combination with MEK inhibition prevented the induction of resistance to the MEK inhibitor cobimetinib or a pharma- ceutically acceptable salt thereof in pancreatic tumors. In one embodiment, treatment with the multi-RTK and JAK2 inhibitor ponatinib or a pharma-ceutically acceptable salt thereof in combination with cobimetinib or a pharma-ceutically acceptable salt thereof is highly effective in targeting pancreatic tumors that are generally refractory to drug treatment regimens currently being explored in the clinic, as described above;

[0018] Pancreatic ductal adenocarcinoma (PDAC) is associated with a prominent involvement of various stromal elements that contribute to aggressive tumor growth, metastasis, immunosuppression, and drug resistance. (Cid-Arregui A,et al.,(2015), Hidalgo M.Pancreatic cancer,The New England Journal of Medicine,2010;362(17):1605-17,Epub 2010 / 04 / 30, Korc M.Pancreatic cancer-associated stroma production,American Journal of Surgery,2007;194(4 Suppl):S84-6,Epub 2007 / 12 / 06, Inman KS,Francis AA,Murray NR.Complex role for the immune system in initiation and progression of pancreatic cancer,World Journal of Gastroenterology,2014;20(32):11160-81,Epub 2014 / 08 / 30、Wormann SM,Diakopoulos KN,Lesina M,Algul H,The immune network in pancreatic cancer development and progression,Oncogene,2014;33(23):2956-67,Epub 2013 / 07 / 16、Moses AG,Maingay J,Sangster K,Fearon KC,Ross JA,Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer:relationship to acute phase response and survival,Oncology Reports,2009;21(4):1091-5,Epub 2009 / 03 / 17、Tjomsland V,Niklasson L,Sandstrom P,Borch K,Druid H,Bratthall C,The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma,Clinical & Developmental Immunology,2011;2011:212810,Epub 2011 / 12 / 23、Silvestris N,Gnoni A,Brunetti AE,Vincenti L,Santini D,Tonini G,et al.Target therapies in pancreatic carcinoma,Current Medicinal Chemistry,2014;21(8):948-65,Epub 2013 / 09 / 03,Vaccaro V,Sperduti I,Vari S,Bria E,Melisi D,Garufi C,Metastatic pancreatic cancer:Is there a light at the end of the tunnel? World Journal of Gastroenterology,2015;21(16):4788-801.Epub 2015 / 05 / 07,Tuveson DA,Neoptolemos JP,Understanding metastasis in pancreatic cancer:a call for new clinical approaches,Cell,2012;148(1-2):21-3,Epub 2012 / 01 / 24).Tumor-associated macrophages are one of the most common stromal cell types that infiltrate pancreatic tumors and correlate with poor patient outcomes. (Vonderheide RH, Bayne LJ, Inflammatory networks and immune surveillance of pancreatic carcinoma,Current Opinion in Immunology,2013;25(2):200-5,Epub 2013 / 02 / 21, Di Caro G,Cortese N,Castino GF,Grizzi F,Gavazzi F,Ridolfi C,Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy,Gut,2015.Epub 2015 / 07 / 15, Chen SJ, Zhang QB, Zeng LJ, Lian GD, Li JJ, Qian CC, Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China, Curr. Oncol. 2015;22(1):e11-9, Epub 2015 / 02 / 17). Recent studies have further suggested an important role for TAMs in tumor progression and metastasis. (Noy R,Pollard JW.Tumor-associated macrophages:from mechanisms to therapy,Immunity,2014;41(1):49-61,Epub 2014 / 07 / 19, Melero I,Gaudernack G,Gerritsen W,Huber C,Parmiani G,Scholl S,Therapeutic vaccines for cancer: an overview of clinical trials,Nature Reviews Clinical Oncology,2014;11(9):509-24,Epub 2014 / 07 / 09, Drake CG.Combination immunotherapy approaches,Annals of oncology:official journal of the European Society for Medical Oncology / ESMO,2012;23 Suppl 8:viii41-6,Epub 2012 / 08 / 29, Weden S, Klemp M, Gladhaug IP, Moller M, Eriksen JA, Gaudernack G, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras, International Journal of Cancer, Journal International du Cancer,2011;128(5):1120-8,Epub 2010 / 05 / 18, Bronte V,Murray PJ.Understanding local macrophage phenotypes in disease:modulating macrophage function to treat cancer,Nature Medicine,2015;21(2):117-9,Epub 2015 / 02 / 06). Our findings imply a role for the STAT3 signaling axis in both tumor cells and TAMs in PDAC in response to MEK inhibition. Our results further suggest that co-treatment of MEK inhibitors, such as cobimetinib / PDGFRα, S6, with multikinase inhibitors targeting STAT3, such as ponatinib, can target both myeloid and cancer cells within primary tumors, resulting in increased cell death and tumor regression.

[0019] The subject matter disclosed herein will be described more fully hereafter. However, many modifications and other embodiments of the subject matter disclosed herein described will occur to those skilled in the art to which the subject matter disclosed herein pertains having the benefit of the teachings set forth in the preceding description. Therefore, it should be understood that the subject matter disclosed herein should not be limited to the specific embodiments disclosed, and modifications and other embodiments are intended to be included within the scope of the appended claims. In other words, the subject matter described herein encompasses all alternatives, modifications, and equivalents. In the event that one or more of the incorporated documents, patents, and similar materials differ or conflict with this application, including but not limited to defined terms, term usage, described techniques, and the like, this application shall prevail. Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference in their entirety.

[0020] I. Definition The term "pancreatic cancer" refers to neoplasms originating from the pancreas. Pancreatic cancer includes exocrine and endocrine cancers. Most pancreatic cancers are exocrine tumors. Pancreatic endocrine tumors are also called islet cell tumors. Unfortunately, currently, the prognosis of pancreatic cancer is poor even when detected early. Pancreatic cancers that can be treated with the methods described herein include, but are not limited to, exocrine and endocrine pancreatic cancers. Exocrine pancreatic cancers include, but are not limited to, adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, mucinous carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, hepatoid adenocarcinoma, intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, pancreatoblastoma, serous cystadenoma, signet ring cell carcinoma, solid pseudopapillary neoplasm, ductal carcinoma, and undifferentiated carcinoma. In some embodiments, the exocrine pancreatic cancer is ductal carcinoma. Pancreatic endocrine cancers include, but are not limited to, insulinoma and glucagonoma.

[0021] In some embodiments, the pancreatic cancer is early stage pancreatic cancer, non-metastatic pancreatic cancer, primary pancreatic cancer, resected pancreatic cancer, advanced pancreatic cancer, locally advanced pancreatic cancer, metastatic pancreatic cancer, unresectable pancreatic cancer, pancreatic cancer in remission, recurrent pancreatic cancer, adjuvant therapy, or neoadjuvant therapy. In some embodiments, the pancreatic cancer is locally advanced pancreatic cancer, unresectable pancreatic cancer, or metastatic pancreatic ductal carcinoma. In some embodiments, the pancreatic cancer is resistant to gemcitabine-based therapy. In some embodiments, the pancreatic cancer is refractory to gemcitabine-based therapy.

[0022] The methods described herein can be used for any one or more of the following purposes: alleviating one or more symptoms of pancreatic cancer, delaying the progression of pancreatic cancer, reducing pancreatic cancer tumor size, disrupting (e.g., destroying) pancreatic cancer stroma, inhibiting pancreatic tumor growth, increasing overall survival, increasing disease-free survival, increasing time to pancreatic cancer disease progression, preventing or delaying pancreatic cancer tumor metastasis, reducing (e.g., eradicating) existing pancreatic cancer tumor metastasis, reducing the occurrence or burden of existing pancreatic cancer tumor metastasis, preventing recurrence of pancreatic cancer, and / or improving clinical benefit for pancreatic cancer patients.

[0023] The method of treating pancreatic cancer described herein includes administering to a subject (human or animal) in need of treatment a therapeutically effective amount of a combination of a MEK inhibitor or a pharma- ceutically acceptable salt thereof and a multikinase inhibitor targeting PDGFRα, S6, and STAT3 or a pharma- ceutically acceptable salt thereof to inhibit, slow, or reverse the growth, development, or spread of pancreatic cancer, including primary and metastatic tumors. Such administration constitutes a method for the treatment or prevention of a disease mediated by one or more kinases and / or survival pathways inhibited by one of the administered active agents. The "administration" or "administering" of the compounds disclosed herein includes the delivery of the active agent, or a prodrug or other pharma- ceutically acceptable derivative thereof, to the recipient using any suitable formulation or route of administration described herein. The MEK inhibitor and the multikinase inhibitor can be administered in either order, sequentially, sequentially, or a combination of both.

[0024] The term "subject" refers to animals such as mammals, including but not limited to primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In certain embodiments, the subject is a human.

[0025] The terms "prevention" or "prophylactic" refer to the continued absence of symptoms of a disease or condition that would be expected if the combination was not administered.

[0026] As used herein, the term "synergistic" refers to a therapeutic combination that is more effective than the additive effect of two or more single agents. The determination of synergistic interaction between a multikinase inhibitor targeting PDGFRα, S6, and STAT3 and a MEK inhibitor can be based on the results obtained from the assays described herein. For example, the in vivo or in vitro methods disclosed herein. The results of these assays can be analyzed using the combination method of Chou and Talalay and dose-effect analysis by CalcuSyn software to obtain a combination index (Chou and Talalay, 1984, Adv. Enzyme Regul. 22:27-55). The combinations provided can be evaluated in one or more assay systems, and the data can be analyzed utilizing standard programs for quantifying synergy, additivity, and antagonism between anticancer drugs. Exemplary programs are described by Chou and Talalay in New Avenues in Developmental Cancer Chemotherapy, Academic Press, 1987, Chapter 2. A combination index value of less than 0.8 indicates synergy, a value of more than 1.2 indicates antagonism, and a value between 0.8 and 1.2 indicates additive effects. Combination therapeutics can provide "synergistic effects" and demonstrate "synergistic," i.e., effects achieved when the active agents used together are greater than the sum of the effects resulting from using the compounds separately. Synergistic effects can be achieved when the active agents are: (1) co-formulated and administered or delivered simultaneously in a combined unit dosage formulation, (2) delivered as separate formulations, alternating or in parallel, or (3) by other dosing schedules. When delivered in alternation therapy, synergistic effects can be achieved when the compounds are administered or delivered sequentially, e.g., by different injections in separate syringes. Generally, during alternation therapy, effective doses of each active agent are administered sequentially, i.e., consecutively, whereas in combination therapeutics, effective amounts of two or more active agents are administered together.Combination effects can be assessed using both the Bliss independence model and the highest single agent (HSA) model (Lehar et al., Molecular Systems Biology, 3:80 (2007)). The Bliss score quantifies the degree of potentiation from the single agents, and a positive Bliss score (greater than 0) suggests greater than simple additivity. A cumulative positive Bliss score of greater than 250 is considered strong synergy observed within the concentration range tested. An HSA score (greater than 0) suggests a combination effect that is greater than the maximum of the single agent responses at the corresponding concentrations.

[0027] "Spheroid" refers to cell cultures known in the art as three-dimensional (3D) cell cultures in an artificial environment in which biological cells grow or interact with their surroundings in all three dimensions. Unlike 2D environments such as petri dishes, 3D cell cultures allow cells to grow in all directions in vitro, similar to how they grow in vivo. The artificial environment includes a medium that provides specific nutrients and other factors that allow cells to grow. The medium described herein provides an environment for rapid cell culture. The term "rapid" refers to a period of time that is shorter than the period required for the same cell growth in a comparison medium.

[0028] The term "contact" or "contacting" means bringing an active agent into sufficient proximity to a target enzyme or survival pathway such that the active agent can bind to the target and inhibit, decrease or reduce its activity.

[0029] As used herein, the term "mammal" refers to humans and all other mammals. As used herein, the term "mammal" includes a "subject" or "patient" and refers to a warm-blooded animal. Guinea pigs, dogs, cats, rats, mice, horses, goats, cows, sheep, zoo animals, farm animals, primates, and humans are all understood to be examples of animals within the meaning of this term.

[0030] As used herein, a "mammal in need thereof" is a subject who has been diagnosed with the particular condition intended to be treated, e.g., pancreatic cancer or a particular type of pancreatic cancer.

[0031] The terms "treat" and "treatment" refer to both therapeutic treatment and prophylactic or preventative measures, the purpose of which is to prevent or slow (alleviate) undesirable physiological changes or disorders, such as the onset or spread of cancer. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, alleviation of disease symptoms, reduction in the extent of disease, stabilization of the disease state (i.e., does not worsen), delay or slowing of disease progression, remission or reversal of the disease state, and remission (partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival in the absence of treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0032] The use of the term "inhibitor" herein is meant to refer to a molecule that inhibits the activity of a target enzyme. As used herein, "inhibit" refers to reducing the activity of a target enzyme compared to the activity of that enzyme in the absence of the inhibitor. In some embodiments, the term "inhibit" refers to a reduction in MEK activity or a reduction in a particular survival pathway of cancer cells by at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%. In other embodiments, inhibition refers to a reduction in activity by about 5% to about 25%, about 25% to about 50%, about 50% to about 75%, or about 75% to 100%. In some embodiments, inhibition refers to a reduction in activity by about 95% to 100%, e.g., a reduction in activity by 95%, 96%, 97%, 98%, 99%, or 100%. Such a decrease can be measured using a variety of techniques, including in vitro kinase assays, as will be appreciated by those of skill in the art.

[0033] As used herein, a "MEK inhibitor" is a molecule that reduces, inhibits, or otherwise diminishes one or more biological activities of MEK (MEK1 and / or MEK2). Activity may decrease the activity of MEK by a statistically significant amount, including, for example, at least about a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95% or 100% decrease, as compared to a suitable control.

[0034] As used herein, a "multikinase inhibitor" is a molecule that reduces, inhibits, or otherwise diminishes the biological activity of PDGFRα, S6, and STAT3. A suitable multikinase inhibitor exhibits activity against each of these three targets and may have activity against additional targets. For example, in an embodiment, the multikinase inhibitor further acts on tumor-associated macrophages associated with pancreatic tumors. The ability of the multikinase inhibitor to act on each of these targets when combined with a MEK inhibitor provides superior efficacy against pancreatic cancer. The activity may reduce the activity of the target by a statistically significant amount, including, for example, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95% or 100% reduction, compared to a suitable control.

[0035] The compounds of the present disclosure may or may not be specific inhibitors. By "specific inhibitor" is intended an agent that reduces, inhibits, or otherwise diminishes the activity of a defined target more than the activity of an unrelated target. For example, a MEK-specific antagonist reduces at least one biological activity of MEK in an amount that is significantly greater than the inhibitory effect of the antagonist on any other protein (e.g., other serine / threonine kinases). In some embodiments, the IC50 of the antagonist on the target is about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.1%, 0.01%, 0.001%, or less than the IC50 of the antagonist on a non-target. A specific MEK inhibitor reduces the biological activity of one or more family members of MEK in an amount that is significantly greater than the inhibitory effect of the antagonist on any other protein (e.g., other serine / threonine kinases). In some of these embodiments, the IC50 of the MEK inhibitor against RAF is about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 0.1%, 0.01%, 0.001%, or less than the IC50 of the MEK inhibitor against other serine / threonine kinases, other MEK family members, or other types of kinases (e.g., tyrosine kinases).

[0036] The term "target" or "targeting" refers to the ability of an active agent to act specifically on a particular MEK enzyme or a particular enzyme associated with a survival pathway. The ability of an active agent to target an enzyme can be determined through routine experimentation as described herein or using other known methods.

[0037] As used herein, "survival pathway" refers to an adaptive mechanism or ability that promotes the survival and proliferation of cancer cells and becomes resistant to active agents. As used herein, the survival pathway is associated with PDGFRα, S6, and STAT3.

[0038] The phrase "therapeutically effective amount" refers to an amount of active agent that (i) treats or prevents pancreatic cancer, (ii) reduces, ameliorate, or eliminates one or more symptoms of pancreatic cancer, or (iii) prevents or delays the onset of one or more symptoms of pancreatic cancer. A therapeutically effective amount of drug can reduce the number of cancer cells, reduce tumor size, inhibit (i.e., slow to some extent and preferably stop) cancer cell invasion into peripheral organs, inhibit (i.e., slow to some extent and preferably stop) tumor metastasis, inhibit tumor growth to some extent, and / or alleviate to some extent one or more symptoms associated with cancer. To the extent that a drug can prevent growth and / or kill existing cancer cells, it can be cytostatic and / or cytotoxic. In the case of cancer treatment, efficacy can be measured, for example, by assessing the time to disease progression (TTP) and / or determining the response rate (RR).

[0039] The term "pharmaceutically acceptable salt" refers to a salt that is not biologically or otherwise undesirable. Pharmaceutically acceptable salts include both acid and base addition salts. The phrase "pharmaceutically acceptable" indicates that a substance or composition must be chemically and / or toxicologically compatible with the other ingredients that make up the formulation and / or with the mammal being treated therewith. As used herein, the phrase "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a molecule. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tanate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Pharmaceutically acceptable salts may include another molecule, such as acetate, succinate, or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. In addition, pharmaceutically acceptable salts may have more than one charged atom in their structure.When multiple charged atoms are part of pharmaceutically acceptable salts, they may have multiple counterions.Therefore, pharmaceutically acceptable salts may have more than one charged atom and / or more than one counterion.Examples include, but are not limited to, the fumarate or hemifumarate salts of cobimetinib and ponatinib HCl.

[0040] Additional definitions are provided below as needed.

[0041] II. In Vivo Methods The disclosed combination of a MEK inhibitor and a multikinase inhibitor targeting PDGFRα, S6, and STAT3 is useful for the treatment of pancreatic cancer.

[0042] In an embodiment, disclosed herein is a method for treating pancreatic cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a combination of active agents, said combination comprising a MEK inhibitor or a pharmaceutically acceptable salt thereof and a multikinase agent that targets PDGFRα, S6 and STAT3 or a pharmaceutically acceptable salt thereof. This embodiment may further comprise inhibiting the proliferation of tumor-associated macrophages.

[0043] Examples of MEK inhibitors that can be used include cobimetinib, GDC-0623, trametinib, binimetinib, selumetinib, pimasertinib, refametinib, PD-0325901 and BI-847325, or pharmaceutically acceptable salts thereof.In one embodiment, the MEK inhibitor is cobimetinib or a pharmaceutically acceptable salt thereof.Cobimetinib has the following structure: [ka]

[0044] Cobimetinib is sold as Cotellic® and is found in the commercial formulation as the hemifumarate salt.

[0045] A useful multikinase agent that targets PDGFRα, S6, and STAT3 is ponatinib, which has the following structure: [ka]

[0046] Ponatinib is sold as Iclusig® and is found in the commercial formulation as the hydrochloride salt.

[0047] Pancreatic cancer includes endocrine and exocrine cancer.In an embodiment, pancreatic cancer is selected from the group consisting of adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, mucinous carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, hepatoid adenocarcinoma, intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, pancreatoblastoma, serous cystadenoma, signet ring cell carcinoma, solid pseudopapillary neoplasm, ductal carcinoma, and undifferentiated carcinoma.In one embodiment, pancreatic cancer is pancreatic ductal adenocarcinoma.

[0048] In an embodiment, the MEK inhibitor or its pharmaceutically acceptable salt and the multikinase inhibitor or its pharmaceutically acceptable salt that targets PDGFRα, S6, and STAT3 are synergistic. That is, the combination provides a higher level of efficacy than the additive effect of both agents. In an embodiment, one or both active agents alone do not show the desired efficacy against pancreatic cancer. In the example of cobimetinib or its pharmaceutically acceptable salt and ponatinib or its pharmaceutically acceptable salt, neither agent alone is known to be effective against pancreatic cancer.

[0049] In an embodiment, the MEK inhibitor or its pharma- ceutically acceptable salt and the multikinase inhibitor or its pharma- ceutically acceptable salt are administered as a combined preparation. In an embodiment, the combined therapeutic agent can be administered as a simultaneous or sequential dosing schedule. When administered sequentially, the combination can be administered in two or more doses. Mixed administration includes co-administration using separate formulations or a single pharmaceutical formulation, and sequential administration in any order, preferably with a period during which both (or all) active agents simultaneously exert their biological activity.

[0050] The method of treating pancreatic cancer is to reduce, inhibit or otherwise reduce the activity of one or more target enzymes or survival pathways.Tumor-associated macrophages associated with pancreatic tumors can also be targeted.The activity of combination can be determined using any method known in the art for measuring the level of MEK activity or PDGFRα, S6, STAT3 and tumor-associated macrophage activation, including in vitro kinase assay, immunoblotting with antibodies specific for phosphorylated targets, or measuring the downstream biological effect of activity.

[0051] Pancreatic cancer can be at early or late stage and can be metastatic. The combinations described herein can be used to treat cancer at any stage, including cancer that has metastasized.

[0052] Treatment of a subject with an effective amount of a combination of a MEK inhibitor and a multi-kinase inhibitor targeting PDGFRα, S6, and STAT3 can include a single treatment or can include a series of treatments.

[0053] Useful amounts of active agents are as described elsewhere herein. In certain embodiments, the MEK inhibitor is administered in an amount of about 5 mg to about 100 mg, or about 45 mg to about 75 mg, and the multikinase inhibitor is administered in an amount of about 5 mg to about 100 mg, or about 30 mg to about 60 mg. In embodiments, the MEK inhibitor is administered in an amount of about 60 mg, and the multikinase inhibitor is administered in an amount of about 45 mg. In embodiments, the administration of the combination therapy is oral once a day. In embodiments, it is preferred that the MEK inhibitor is cobimetinib or a pharma- ceutically acceptable salt thereof, and the multikinase inhibitor is ponatinib or a pharma- ceutically acceptable salt thereof. In some embodiments, each active agent is administered to the subject at a dose of about 0.001 μg / kg to about 1000 mg / kg, including, but not limited to, about 0.001 μg / kg, 0.01 μg / kg, 0.05 μg / kg, 0.1 μg / kg, 0.5 μg / kg, 1 μg / kg, 10 μg / kg, 25 μg / kg, 50 μg / kg, 100 μg / kg, 250 μg / kg, 500 μg / kg, 1 mg / kg, 5 mg / kg, 10 mg / kg, 25 mg / kg, 30 mg / kg, 40 mg / kg, 50 mg / kg, 100 mg / kg, and 200 mg / kg. The amount of each active agent present in the combination composition to be administered may be about 1 mg to about 1000 mg, or about 5 mg to about 100 mg, or about 10 mg to about 80 mg, or about 45 mg to about 75 mg, or about 30 mg to about 60 mg. It is understood that the appropriate dose of the active compound depends on several factors within the knowledge of a skilled artisan or veterinarian. The dose of the active agent will vary depending, for example, on the subject's age, weight, general health, sex, and diet of the subject, the time of administration, the route of administration, the excretion rate, and any drug combinations. It will also be understood that the effective dose used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become evident from the results of diagnostic assays.

[0054] In some embodiments, described herein is a method for treating pancreatic cancer in a subject in need thereof, comprising administering to the subject a combination of a MEK inhibitor or a pharma- ceutically acceptable salt thereof and a multikinase inhibitor targeting PDGFRα, S6, and STAT3 or a pharma- ceutically acceptable salt thereof, and further comprising applying both additional. The additional therapy may be radiation therapy, surgery (e.g., lumpectomy and mastectomy), chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy, immunotherapy, bone marrow transplant, nanotherapy, monoclonal antibody therapy, or a combination thereof. The additional therapy may be in the form of adjuvant therapy or neoadjuvant therapy. In some embodiments, the additional therapy is administration of an anti-metastatic drug. In some embodiments, the additional therapy is administration of a side effect limiting agent (e.g., an agent intended to reduce the occurrence and / or severity of side effects of a treatment, such as an anti-nausea agent). In some embodiments, the additional therapy is radiation therapy. In some embodiments, the additional therapy is surgery. In some embodiments, the additional therapy is a combination of radiation therapy and surgery. In some embodiments, the additional therapy is gamma irradiation.

[0055] In some embodiments, the treatment results in a sustained response in the subject after the treatment is stopped. "Sustained response" refers to the sustained effect of reducing tumor growth after the treatment is stopped. For example, the tumor size can remain the same or smaller compared to the size at the beginning of the administration phase. In some embodiments, the sustained response has a duration at least equal to the treatment period, or at least 1.5 times, 2.0 times, 2.5 times, or 3.0 times the treatment period.

[0056] The therapeutic method disclosed herein may result in partial or complete response.As used herein, "complete response" or "CR" refers to the disappearance of all target lesions, "partial response" or "PR" refers to the reduction of the sum of the longest diameters (SLD) of target lesions by at least 30% based on baseline SLD, and "stable disease" or "SD" refers to the target lesions not shrinking enough to qualify for PR or increasing enough to qualify for PD based on the smallest SLD since the start of treatment.As used herein, "overall response rate" (ORR) refers to the sum of complete response (CR) rate and partial response (PR) rate.

[0057] The treatment method disclosed herein can result in increased progression-free survival and overall survival of the subjects administered the combination therapy.As used herein, "progression-free survival" (PFS) refers to the length of time during and after treatment during which the disease (e.g., cancer) being treated does not worsen.Progression-free survival can include the length of time that a patient experiences complete or partial remission, and the length of time that a patient experiences stable disease.

[0058] As used herein, "overall survival" refers to the proportion of subjects in a group who are likely to be alive after a particular period of time.

[0059] In some embodiments, the subject to which the combination is administered is a mammal, such as a domestic animal (e.g., cows, sheep, cats, dogs, and horses), a primate (e.g., humans and non-human primates such as monkeys), a rabbit, and a rodent (e.g., a mouse and a rat). In some embodiments, the subject to be treated is a human.

[0060] A subject in need of treatment for pancreatic cancer may be one who exhibits symptoms of cancer, has been diagnosed with cancer, is in remission from pancreatic cancer, or is at high risk of developing cancer (e.g., due to a genetic predisposition, exposure to certain diets or environments).

[0061] Many of the combinations described herein will be determined to be synergistic.

[0062] The in vitro method described herein uses a method of preparing spheroid cell cultures that includes culturing cells in a medium that includes serum that is scalded before being added to the medium for culture. It has been discovered that the medium can be modified to rapidly culture 3-D spheroids. The modified medium is prepared by scalding fetal bovine serum (FBS) before contacting it with the cells to be cultured. In an embodiment, the FBS is scalded at 95-100°C for 10 minutes, at which point the color of the serum turns yellow. The scalded FBS is then centrifuged at 8000 x g for 20 minutes and filtered through a sterile Corning vacuum filter unit with a filter pore size of 0.22 μm. A useful medium includes about 5% to about 20% (v / v) fetal bovine serum. Medium for spheroid culture is prepared by adding 10% (v / v) boiled FBS to RPMI medium supplemented with 2 mM L-glutamine, 100 units ml-1 of penicillin and streptomycin. Spheroid medium should be prepared fresh before use. Boiled FBS can be stored at 4°C for 2-3 months. Medium for monolayer culture is prepared by adding 10% (v / v) normal FBS to RPMI medium supplemented with 2 mM L-glutamine, 100 units ml-1 of penicillin and streptomycin. Medium for migration assay is prepared by adding 20% ​​(v / v) normal FBS to RPMI medium supplemented with 2 mM L-glutamine, 100 units ml-1 of penicillin and streptomycin.

[0063] III. Combination Pharmaceutical Compositions In an embodiment, the subject matter described herein relates to a combination of a) a MEK inhibitor, or a pharma- ceutically acceptable salt thereof, and b) a multikinase inhibitor targeting PDGFRα, S6, and STAT3, or a pharma- ceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of pancreatic cancer.

[0064] In an embodiment, the subject matter described herein relates to a pharmaceutical composition comprising an effective amount of a combination of a MEK inhibitor or a pharma- ceutical acceptable salt thereof and a multikinase agent that targets PDGFRα, S6, and STAT3 or a pharma- ceutical acceptable salt thereof, and a pharma- ceutical acceptable excipient. In a particular embodiment, the pharmaceutical composition is for the treatment of pancreatic cancer.

[0065] In an embodiment, the composition comprises a MEK inhibitor selected from the group consisting of cobimetinib, GDC-0623, trametinib, binimetinib, selumetinib, pimasertinib, refametinib, PD-0325901 and BI-847325, or a pharmaceutically acceptable salt thereof.In one embodiment, the MEK inhibitor is cobimetinib or a pharmaceutically acceptable salt thereof.In a particular embodiment, the MEK inhibitor is cobimetinib hemifumarate.

[0066] In an embodiment, the multikinase agent is ponatinib or a pharma- ceutically acceptable salt thereof. In one embodiment, the multikinase inhibitor is ponatinib hydrochloride.

[0067] In an embodiment, the composition comprises cobimetinib or a pharma- ceutically acceptable salt thereof and ponatinib or a pharma- ceutically acceptable salt thereof.In an embodiment, the composition comprises cobimetinib hemifumarate and ponatinib hydrochloride.

[0068] The amount of each active agent present in the combination can be from about 1 mg to about 1000 mg, or from about 5 mg to about 100 mg, or from about 10 mg to about 80 mg, or from about 45 mg to about 75 mg, or from about 30 mg to about 60 mg. In embodiments, the MEK inhibitor is present in an amount of from about 45 mg to about 75 mg and the multikinase inhibitor is present in an amount of from about 30 mg to about 60 mg.

[0069] A combination therapy can provide a "synergistic effect" and be described as "synergistic", i.e., the effect achieved when active agents are used together is greater than the sum of the effects resulting from using these active agents separately. A synergistic effect can be achieved when the active agents are: (1) co-formulated and administered or delivered simultaneously in a combined unit dosage formulation, (2) delivered as separate formulations, alternating or in parallel, or (3) by other dosing schedules. When delivered in alternation therapy, a synergistic effect can be achieved when the active agents are administered or delivered sequentially, for example, by different injections in separate syringes, separate pills or capsules, or separate infusions. Generally, during alternation therapy, an effective dose of each active agent is administered sequentially, i.e., consecutively, whereas in a combination therapy, an effective amount of two or more active agents is administered together.

[0070] The MEK inhibitor and / or the multikinase inhibitor, each of which is also referred to herein as an active agent, can be formulated as a pharmaceutical composition according to standard pharmaceutical practice.The exemplary multikinase inhibitor, ponatinib, is available as a tablet for oral administration in strengths of 15 mg, 30 mg, and 45 mg.The exemplary MEK inhibitor, cobimetinib, is available as a tablet for oral administration in strengths of 20 mg.However, according to this embodiment, other pharmaceutical compositions are provided that include the MEK inhibitor or the multikinase inhibitor or both together with a pharma- ceutically acceptable excipient, such as a carrier or diluent.

[0071] A typical formulation is prepared by mixing the active agent with one or more excipients. Suitable excipients are well known to those skilled in the art and include substances such as carbohydrates, waxes, water-soluble and / or swellable polymers, hydrophilic or hydrophobic substances, gelatin, oils, solvents, water, etc. The particular excipient used will depend on the means and purpose for which the active agent is being applied. Solvents are generally selected based on solvents recognized by those skilled in the art as safe (GRAS) for administration to mammals. In general, safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG400, PEG300), etc., and mixtures thereof. The formulation may also include one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifying agents, glidants, processing aids, colorants, sweeteners, fragrances, flavoring agents, and other known additives to provide elegant presentation of the active agent or to aid in the manufacture of a pharmaceutical product (i.e., a medicament).

[0072] The formulation can be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (i.e., the active agent or a stabilized form of the active agent (e.g., a complex with a cyclodextrin derivative or other known complexing agent)) is dissolved in a suitable solvent in the presence of one or more of the excipients described above. The active agent is typically formulated into a pharmaceutical dosage form to provide an easily controllable dosage of the drug and to enable patient compliance with the prescribed dosing regimen.

[0073] The pharmaceutical composition (or formulation) for application can be packaged in a variety of ways depending on the method used to administer the drug. Generally, the article for distribution includes a container with the pharmaceutical formulation therein in an appropriate form. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like. The container may also include a tamper-evident combination material to prevent inadvertent access to the package contents. Additionally, the container has a label affixed thereon that describes the contents of the container. The label may also include appropriate warnings. In one embodiment, the container is a blister pack.

[0074] Pharmaceutical formulations can be prepared for various routes and forms of administration. For example, an active agent having a desired degree of purity can be mixed, optionally with pharma- ceutically acceptable excipients, in a lyophilized formulation, a ground powder, or in an aqueous solution (Remington's Pharmaceutical Sciences (1980) 16th edition, Osol, A. Ed., Mack Publishing Co., Easton, PA). Formulation can be carried out by mixing the active agent at the desired purity at an appropriate pH at ambient temperature with a physiologically acceptable carrier, i.e., a carrier that is non-toxic to the recipient at the dosage and concentration used. The pH of the formulation depends mainly on the particular application and the concentration of the compound, but can range from about 3 to about 8. Formulation in acetate buffer at pH 5 is a preferred embodiment.

[0075] The active agent can be sterile. In particular, formulations to be used for in vivo administration must be sterile. Such sterilization is readily accomplished by filtration through sterile filtration membranes.

[0076] The active agent may generally be stored as a solid composition, a lyophilized formulation, or an aqueous solution.

[0077] Pharmaceutical compositions containing active agents can be formulated, administered and administered in a manner, i.e., amount, concentration, schedule, course of treatment, vehicle and route of administration, consistent with good medical practice. Factors to be considered in this regard include the particular injury being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the injury, the site of delivery of the agent, the method of administration, the dosing schedule, and other factors known to medical practitioners. The "therapeutically effective amount" of the compound to be administered will be governed by such considerations. Acceptable excipients are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; serum albumin, gelatin, or immunoglobulin, etc. amino acids, such as glycine, glutamine, asparagine, histidine, arginine, lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants, such as polysorbates (e.g., TWEEN™), poloxamers (e.g., PLURONICS™), or polyethylene glycol (PEG).The active agent may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences.

[0078] The sustained release formulation of active agent can be prepared.Suitable examples of sustained release formulation include semipermeable matrix of solid hydrophobic polymer containing active agent, matrix is ​​in the form of shaped article, for example, film or microcapsule.Examples of sustained release matrix include polyester, hydrogel (for example, poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactide (US3773919), copolymer of L-glutamic acid and γ-ethyl-L-glutamate, degradable lactic acid-glycolic acid copolymer (LUPRON DEPOT™), such as injectable microspheres composed of non-degradable ethylene-vinyl acetate, lactic acid-glycolic acid copolymer and leuprolide acetate, and poly-D-(-)-3-hydroxybutyric acid.

[0079] The formulations include those suitable for the administration route detailed herein.The formulations may be conveniently provided in unit dosage form and may be prepared by any method well known in the field of pharmacy.Techniques and formulations are generally found in Remington's Pharmaceutical Sciences.Such methods include the step of bringing active agent into association with carriers which constitute one or more accessory ingredients.In general, the formulations are produced by uniformly and intimately bringing active agent into association with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0080] Formulations of the active agent suitable for oral administration can be prepared as discrete units such as pills, capsules, cachets or tablets, each containing a predetermined amount of the active agent.

[0081] Compressed tablets can be prepared by compressing in a suitable machine the active agent in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active agent or dispersing agent. Molded tablets can be produced by molding in a suitable machine a mixture of the powdered active agent moistened with an inert liquid diluent. The tablets can be optionally coated or scored, and are optionally formulated to provide slow or controlled release of the active agent therefrom.

[0082] Tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, such as gelatin capsules, syrups or elixirs can be prepared for oral use. Preparations of active agents intended for oral use can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents, including sweeteners, flavoring agents, coloring agents and preservatives, to provide a palatable preparation. Tablets containing active agents mixed with pharma- ceutically acceptable non-toxic excipients suitable for the manufacture of tablets are acceptable. These excipients may be, for example, inert diluents such as calcium or sodium carbonate, lactose, calcium or sodium phosphate, granulating and disintegrating agents such as corn starch or alginic acid, binding agents such as starch, gelatin, or acacia, and lubricants such as magnesium stearate, stearic acid, talc, etc. The tablets may be uncoated or they may be coated by known techniques including microencapsulation to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period, for example by using a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax.

[0083] Aqueous suspensions of the active agent contain the agent in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include suspending agents such as sodium carboxymethylcellulose, croscarmellose, povidone, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as natural phosphatides (e.g., lecithin), condensation products of alkylene oxides with fatty acids (e.g., polyoxyethylene stearates), condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., heptadecaethyleneoxycetanol), condensation products of ethylene oxide with fatty acids and partial esters derived from hexitol anhydrides (e.g., polyoxyethylene sorbitan monooleate). Aqueous suspensions may also contain one or more preservatives, such as ethyl p-hydroxybenzoate or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0084] The pharmaceutical composition of the active agent may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents as described above. The sterile injectable preparation may be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as 1,3-butanediol. The sterile injectable preparation may also be prepared as a lyophilized powder. Acceptable vehicles and solvents that may be used are water, Ringer's solution, and physiological saline solution. In addition, sterile, fixed oils may be conventionally used as a solvent or suspending medium. For this purpose, any non-irritating fixed oil may be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may also be used in the preparation of injectables.

[0085] The amount of active agent that can be combined with a carrier material to produce a single dosage form can vary depending on the host being treated and the particular method of administration. For example, a sustained release formulation intended for oral administration to humans can contain about 1 to 1000 mg of active agent combined with an appropriate and convenient amount of carrier material, which can vary from about 5 to about 95% (weight:weight) of the total composition. Pharmaceutical compositions can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion can contain about 3-500 μg of active agent per milliliter of solution, such that infusion of a suitable volume can occur at a rate of about 30 mL / hour.

[0086] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.

[0087] Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

[0088] Formulations suitable for pulmonary or nasal administration have, for example, particle sizes in the range of 0.1 to 500 microns (including particle sizes in the range of 0.1 microns to 500 microns in increments of microns such as 0.5, 1, 30 microns, 35 microns, etc.), which are administered by rapid inhalation through the nasal passages or inhalation through the mouth to reach the alveolar sacs. Suitable formulations include aqueous or oily solutions of the active agent. Formulations suitable for aerosol or dry powder administration can be prepared according to conventional methods and can be delivered with other therapeutic agents, such as compounds previously used in treating or preventing disorders as described below.

[0089] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active agent such carriers as are known in the art to be appropriate.

[0090] The formulations can be packaged in unit-dose or multi-dose containers, for example sealed ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, for example water, immediately prior to use for injection. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those which contain a daily dose or unit daily sub-dose, or an appropriate fraction thereof, of an active agent, as hereinbefore described.

[0091] The subject matter further provides veterinary compositions comprising at least one active agent as defined above together with a veterinary carrier. The veterinary carrier may be a solid, liquid, or gaseous substance that is useful for the purpose of administering the composition and is otherwise inert or acceptable in the veterinary art and compatible with the active agent. These veterinary compositions may be administered parenterally, orally, or by any other desired route.

[0092] IV.Manufactured products In another aspect, described herein is an article of manufacture, e.g., a "kit" containing materials useful for treating pancreatic cancer. The kit includes a container containing a combination of a MEK inhibitor or a pharma- ceutically acceptable salt thereof and a multikinase inhibitor or a pharma- ceutically acceptable salt thereof targeting PDGFRα, S6, and STAT3 for treating pancreatic cancer. The kit may further include a label or package insert on or associated with the container. The term "package insert" is used to refer to instructions typically included in commercial packages of therapeutic products, including information about indications, usage, dosage, administration, contraindications, and / or warnings regarding the use of such therapeutic products. Suitable containers include, for example, bottles, vials, syringes, blister packs, and the like. The container may be formed from a variety of materials, such as glass or plastic. The container holds a combination of a MEK inhibitor or a pharma- ceutically acceptable salt thereof and a multikinase inhibitor or a pharma- ceutically acceptable salt thereof that is effective for treating a condition, and may have a sterile access port (e.g., the container may be an intravenous solution bag or vial having a stopper pierceable by a hypodermic needle). The label or package insert indicates that the composition is used to treat pancreatic cancer. Alternatively, or in addition, the article of manufacture may further comprise a second container containing a pharma- ceutically acceptable buffer, such as bacteriostatic solution for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further comprise other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0093] The kit may further comprise instructions for administration of the MEK inhibitor or a pharma- ceutically acceptable salt thereof, and the multikinase inhibitor or a pharma- ceutically acceptable salt thereof, if formulated separately.For example, if the kit comprises a first composition comprising a MEK inhibitor or a pharma- ceutically acceptable salt thereof, and a second pharmaceutical formulation comprising a multikinase inhibitor or a pharma- ceutically acceptable salt thereof, the kit may further comprise instructions for simultaneous, sequential, or separate administration of the first and second pharmaceutical compositions to a patient in need of treatment.

[0094] In another embodiment, the kit is suitable for delivery of a solid oral form of the combination of the MEK inhibitor or its pharma- ceutically acceptable salt and the multikinase inhibitor or its pharma- ceutically acceptable salt. Such a kit preferably includes a plurality of unit doses. Such a kit may include a card with the doses arranged in the order of their intended use. An example of such a kit is a "blister pack". Blister packs are well known in the packaging industry and are widely used for packaging pharmaceutical unit dosage forms. Optionally, a memory aid can be provided, for example in the form of numbers, letters, or other markings, or by a calendar insert that designates the days of the treatment schedule on which the doses can be administered.

[0095] According to one embodiment, the kit may include (a) a first container containing a MEK inhibitor or a pharma- ceutically acceptable salt thereof, and optionally (b) a second container containing a multikinase inhibitor or a pharma- ceutically acceptable salt formulation thereof. Alternatively, or in addition, the kit may further include a third container containing a pharma- ceutically acceptable buffer, such as bacteriostatic solution for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0096] In other specific embodiments, where the kit comprises a composition of a MEK inhibitor or a pharma- ceutically acceptable salt thereof and a multikinase inhibitor or a pharma- ceutically acceptable salt thereof, the kit may comprise separate bottles or containers containing the separate compositions, such as individually divided foil packets, although the separate compositions may be contained within a single undivided container. Typically, the kit includes instructions for administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), when administered at different dosing intervals, or when titration of the individual components of the combination is desired by the prescribing physician.

[0097] In yet another embodiment, the problem described herein relates to a medium using pre-scalded serum, i.e., serum that has been scalded for a certain period of time before use in the medium. This medium results in rapid formation of spheroids compared to a medium using normal serum that is not scalded. In an embodiment, the medium for culturing cells comprises about 10% scalded fetal bovine serum, the serum being scalded at 95-100°C for 10 minutes before being added to the medium.

[0098] The subject matter described herein includes the following specific embodiments.

[0099] 1. A method of treating pancreatic cancer in a subject in need thereof, comprising administering to the subject an effective amount of a combination of active agents, the combination comprising a MEK inhibitor, or a pharma- ceutically acceptable salt thereof, and a multikinase agent that targets PDGFRα, S6, and STAT3, or a pharma- ceutically acceptable salt thereof.

[0100] 2. The method of embodiment 1, wherein the MEK inhibitor is selected from the group consisting of cobimetinib, GDC-0623, trametinib, binimetinib, selumetinib, pimasertinib, refametinib, PD-0325901, and BI-847325, or a pharmaceutically acceptable salt thereof.

[0101] 3. The method according to any of the preceding embodiments, wherein said MEK inhibitor is selected from the group consisting of cobimetinib, and trametinib, or a pharma- ceutically acceptable salt thereof.

[0102] 4. The method according to any of the preceding embodiments, wherein said MEK inhibitor is cobimetinib or a pharma- ceutically acceptable salt thereof.

[0103] 5. The method of any of the preceding embodiments, wherein said multikinase agent is ponatinib or a pharma- ceutically acceptable salt thereof.

[0104] 6. The method of any of the above embodiments, wherein said pancreatic cancer is an endocrine cancer.

[0105] 7. The method of any of the above embodiments, wherein said pancreatic cancer is an exocrine cancer.

[0106] 8. The method according to any of the above embodiments, wherein the pancreatic cancer is adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, mucinous carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, hepatoid adenocarcinoma, intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, pancreatoblastoma, serous cystadenoma, signet ring cell carcinoma, solid pseudopapillary tumor, ductal carcinoma, and undifferentiated carcinoma.

[0107] 9. The method of any of the above embodiments, wherein said pancreatic cancer is pancreatic ductal adenocarcinoma.

[0108] 10. The method of any of the preceding embodiments, wherein said combination is synergistic.

[0109] 11. The method according to any of the previous embodiments, wherein the active agents are administered sequentially.

[0110] 12. The method according to any of the previous embodiments, wherein said active agents are administered simultaneously.

[0111] 13. The method according to any of the previous embodiments, wherein said MEK inhibitor and said multikinase inhibitor are administered as a combined formulation.

[0112] 14. The method according to any of the preceding embodiments, wherein said MEK inhibitor is administered in an amount of about 45 mg to about 75 mg, and said multikinase inhibitor is administered in an amount of about 30 mg to about 60 mg.

[0113] 15. The method according to any of the previous embodiments, wherein said amount is administered once a day.

[0114] 16. The method of any of the previous embodiments, wherein the MEK inhibitor is cobimetinib, or a pharma- ceutically acceptable salt thereof, such as cobimetinib hemifumarate, and the multikinase inhibitor is ponatinib, or a pharma- ceutically acceptable salt thereof, such as ponatinib HCl.

[0115] 17. A combination of a) a MEK inhibitor, or a pharma- ceutical acceptable salt thereof, and b) a multikinase inhibitor targeting PDGFRα, S6, and STAT3, or a pharma-ceutical acceptable salt thereof, for the prophylactic or therapeutic treatment of pancreatic cancer.

[0116] 18. A pharmaceutical composition comprising an effective amount of a combination of a MEK inhibitor or a pharma- ceutical acceptable salt thereof and a multikinase agent that targets PDGFRα, S6, and STAT3 or a pharma- ceutical acceptable salt thereof, and a pharma- ceutical acceptable excipient, wherein the composition is for the treatment of pancreatic cancer.

[0117] 19. The composition of any of the preceding embodiments, wherein the MEK inhibitor is selected from the group consisting of cobimetinib, GDC-0623, trametinib, binimetinib, selumetinib, pimasertinib, refametinib, PD-0325901, and BI-847325, or a pharmaceutically acceptable salt thereof.

[0118] 20. The composition of any of the preceding embodiments, wherein the MEK inhibitor is selected from the group consisting of cobimetinib, and trametinib, or a pharma- ceutically acceptable salt thereof.

[0119] 21. The composition of any of the preceding embodiments, wherein the MEK inhibitor is cobimetinib or a pharma- ceutically acceptable salt thereof.

[0120] 22. The composition of any of the preceding embodiments, wherein the multikinase agent is ponatinib or a pharma- ceutically acceptable salt thereof.

[0121] 23. The composition of any of the previous embodiments comprising cobimetinib, or a pharma- ceutically acceptable salt thereof, and ponatinib, or a pharma-ceutically acceptable salt thereof.

[0122] 24. The composition of any of the preceding embodiments, wherein the MEK inhibitor or a pharma- ceutically acceptable salt thereof is present in an amount of about 45 mg to about 75 mg, and the multikinase inhibitor or a pharma- ceutically acceptable salt thereof is present in an amount of about 30 mg to about 60 mg.

[0123] 25. A kit comprising a MEK inhibitor or a pharma- ceutically acceptable salt thereof, a multikinase agent or a pharma- ceutically acceptable salt thereof that targets PDGFRα, S6, and STAT3, a container, and a package insert or label.

[0124] The following examples are offered by way of illustration and not by way of limitation. EXAMPLES

[0125] Materials and Methods Cell lines and reagents: All cell lines were from ATCC, except for PA-TU-8988T cells from DSMZ, and SUIT-2 cells from JCRB. All cell lines were deposited in the Genentech Cell Line Core Facility, where SNP and STR analysis was routinely performed to confirm cell line identity. All cell lines were routinely cultured in RPMI medium (Gibco) supplemented with 10% FBS, 2 mM L-glutamine, 100 units ml-1 penicillin and streptomycin. Rapamycin and ponatinib were obtained from Selleckchem, crenolanib from Arog Pharmaceuticals, and cobimetinib, GDC-0941, and GDC-0980 were synthesized at Genentech. The human phosphokinase array kit was from R&D Systems (ARY003B), the Cignal-45-Pathway reporter assay was from Qiagen (CCA-901L), the human tyrosine kinase RT2 Profiler PCR array was from Qiagen (PAHS-161Z), and the MDSC isolation kit was from Miltenyi Biotec. All assays using these kits were performed according to the manufacturer's instructions.

[0126] Western blotting and cell viability assays: Cells were seeded in 10 cm dishes and treated with 1 μM small molecule inhibitors for 24 h. Cell lysates were prepared in RIPA lysis buffer (Thermo Scientific) containing protease inhibitor cocktail (Thermo Scientific), SDS-PAGE was performed, and proteins were transferred to nitrocellulose membranes. Immunoblotting was performed using standard methods. Protein bands were quantified using ImageJ software. Primary antibodies: p-Erk, p-STAT3, p-S6, total S6, p-PDGFRα, p-PDGFRβ, p-RSK3, cleaved PARP, Bcl-xL, Mcl, survivin, Rab11, p-Akt, β-actin, GAPDH (Cell Signaling), total STAT3, total PDGFRα (Santa Cruz Biotechnology), p-EphA7 (Gene Tex), and p-EphA2 / 3, EphA2 / 5 (MyBioscource).

[0127] Cell viability assays were performed by treating cells with a dose titration (0.001–10 μM) or a fixed dose (1 μM) of various pharmacological inhibitors for 72 h and measuring viability using CellTiter Glo (Promega). Bliss scores were calculated as previously described. (Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Systematic discovery of multicomponent therapeutics, Proceedings of the National Academy of Sciences of the United States of America, 2003;100(13):7977-82, Epub 2003 / 06 / 12).

[0128] Lentiviral infection: Lentiviral particles against shSTAT3 were generated as previously described. (Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen, Cell, 2006;124(6):1283-98. Epub 2006 / 03 / 28). shSTAT3 in Dox-inducible system was obtained from LakePharma Inc. The target sequence used for shSTAT3 was AATCTTAGCAGGAAGGTGCCT. KP4 and MIA-PACA2 cells were transduced with optimized titers of lentivirus and selected with 1 μg / ml puromycin.

[0129] Luminex Assays and ELISA: Luminex assays on culture supernatants from cancer cells cultured for 72 h or plasma samples taken at the end point from animal studies were performed using a multiplex kit (Bio-Rad) according to the manufacturer's instructions. ELISA for PDGFα was performed using a kit from R&D Systems.

[0130] Invasion assay: Cells in RPMI containing 2% FBS were seeded onto inverted inserts of BD BioCoat Matrigel invasion chambers (BD Biosciences). The lower chamber was filled with RPMI supplemented with 10% FBS as a chemoattractant, and the number of cells that had invaded the lower chamber after 18 h of incubation was measured using a SpectraMax M5 (Molecular Devices).

[0131] Animal testing: All animal studies were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All dosing regimens were well tolerated in xenografts. Two xenograft models were used: the human PDAC-derived cell line KP4, and cells derived from tumors isolated from KPP-GEMM mice. 5 × 106 cells were implanted subcutaneously into the right flank of immunodeficient mice (Charles River Laboratories) without any matrigel. After tumors reached approximately 200 mm3, mice were randomized and treated with vehicle (MCT + 25 mM citrate buffer, pH 2.75), cobimetinib (5 mg / kg) + / - ponatinib (30 mg / kg), PO, QD. Tumor volumes were measured with Ultra-Cal IV calipers at the indicated intervals. A mixed modeling approach was used to adequately analyze repeated measurements of tumor volume from the same animal over time. (Jose Pinheiro DB, Saikat DebRoy, Deepayan Sarkar, R Core team. Linear and Nonlinear mixed effects models. Package 'nlme' 2008). This approach accommodates both repeated measurements and moderate attrition due to all non-treatment-related deaths of animals before the end of the study. Cubic regression splines were used to fit nonlinear profiles to the time course of log2 tumor volume at each dose level. These nonlinear profiles were then related to dose within the mixed model. Tumor growth inhibition (% TGI) as a percentage of vehicle was calculated as the percentage of the area under the fitted curve (AUC) for each dose group per day relative to vehicle using the following formula: %TGI=100×(1−AUC dose / AUC vehicle)

[0132] To determine the uncertainty interval (UI) of the %TGI, the fitted curve and fitted covariance matrix were used to generate a random sample as an approximation to the distribution of the %TGI. The random sample consisted of 1,000 simulated realizations of the fitted mixture model, and the %TGI was recalculated for each realization. The reported UI was the value within which the recalculated value of the %TGI would fall 95% of the time, given the fitted model. The 2.5th and 97.5th percentiles of the simulated distribution were used as the upper and lower UI. Tumor growth inhibition of >60% was considered significant. (Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response, Clinical Cancer Research: an official journal of the American Association for Cancer Research, 2012;18(14):3846-55.Epub 2012 / 06 / 01).

[0133] Plots were implemented and generated using R version 2.8.1 (R Development Core Team 2008; R Foundation for Statistical Computing; Vienna, Austria) and Excel version 12.0.1 (Microsoft Corporation). Data were analyzed using R, version 2.8.1, and mixed models were fitted within R using the nlme package, version 3.1-89 (41).

[0134] Immunohistochemistry and immunofluorescence: Immunohistochemistry and immunofluorescence were performed on formalin-fixed paraffin-embedded cell pellets, whole tissue sections, and 4-μm-thick sections cut from TMA blocks (US Biomax, Inc.). Slides were deparaffinized and antigen retrieval was performed with Target Retrieval Solution (Dako) in a PT Module (Thermo Scientific). Endogenous peroxidase activity was blocked with 3% H2O2, and 3% BSA was used to block endogenous immunoglobulins. Primary antibodies against p-Erk and p-STAT3 (Cell Signaling) were used at 1 μg / ml, p-PDGFRα (Cell Signaling) at 0.4 μg / ml, F4 / 80 (Serotec) at 10 μg / ml, Gr-1 (BD Pharmingen) at 1 μg / ml, cleaved caspase 3 (Cell Signaling) at 0.6 μg / ml, and CD8α (Genentech) at 5 μg / ml. Antibody binding was detected using Vecstatin ABC Elite horseradish peroxidase (Vector Laboratories) or PowerVision poly-HRP (Leica Biosystems) and metal-enhanced 3,3'-diaminobenzidine (Pierce) for IHC staining, and PowerVision poly-HRP (Leica Biosystems) with a TSA kit (Life Technologies) for immunofluorescence staining. Counterstaining of IHC slides was performed with Mayer's hematoxylin (Rowley Biochemical).

[0135] Histology: Whole-slide images were acquired at a final magnification of 200x using a Nanozoomer XR automated slide scanning platform (Hamamatsu, Hamamatsu City, Shizuoka Pref., Japan).

[0136] Microarray and RNA sequencing analysis: Gene expression in normal and PDAC human tissues was measured using Affymetrix HGU133P arrays from Gene Logic. Gene expression data were normalized by the robust multichip average (RMA) method. Expression probe sets 203131_at for human PDGFRα, 202273_at for human PDGFRβ, 205945_at for human IL6-R, and 204171_at for PRS6KB1 were used.

[0137] statistical analysis All data are expressed as mean ± standard error of the mean (SEM). Student's t-test (two-tailed) was used to compare two groups and P values ​​were calculated using Prism or Excel. P<0.05 was considered significant. Survival curves were plotted using the Kaplan-Meier method.

[0138] Example 1: Sensitivity to MEK inhibition in pancreatic cancer cell spheroid cultures To compare how pancreatic cancer cells grown in two-dimensional (2D) and three-dimensional (3D) culture respond to various cancer therapeutics, we treated the KRAS mutant PDAC cancer cell line, KP4, with a panel of 203 small molecule inhibitors of cancer-relevant targets and known chemotherapeutic drugs (Table 1). [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5]

[0139] With regard to 3D culture, described herein are methods to facilitate relatively rapid "high-throughput" analysis. We have consistently observed that culturing cancer cells in medium containing 10% fetal bovine serum, pre-scalded at 95-100°C for 10 min before adding to the culture medium, resulted in the rapid formation of 3D "spheroids". Spheroids formed using this method exhibited all the typical characteristics of previously described spheroids, including low levels of proliferation, with a necrotic / apoptotic center with predominant localization of Ki67 staining in the outer layer, and apoptosis indicated by cleaved caspase-3 by 72 h (Figure 27). Their drug sensitivity patterns were also similar to previously described spheroids (Figures 28 and 29).

[0140] Treatment of KP4 cells in 2D and 3D culture conditions with a panel of 203 compounds revealed differential sensitivity to some agents (Figure 1). 3D cultures are generally more resistant to drug treatment, and KP4 spheroids were indeed significantly more resistant than 2D cultures to a subset of 18 inhibitors from a panel consisting mostly of chemotherapeutic agents (Figure 1). Unexpectedly, we also identified 11 inhibitors that were more effective in 3D cultures than in 2D cultures (Figure 1). These 11 inhibitors consisted of various molecules with reported activity targeting multiple signaling pathways. Four of these inhibitors (cobimetinib, GDC-0623, AZD6244, PD901) target the MEK pathway, three target the PI3K pathway (GDC-0941, GDC-0980, G38390), and one targets the MET pathway (G45203).

[0141] Example 2: Multiple signaling pathways differentially regulated in 2D vs. 3D culture of pancreatic cancer cells To identify signaling pathways that potentially contribute to the observed differential treatment sensitivity of pancreatic cancer cells in 2D vs. 3D, we performed phosphokinase arrays, gene expression arrays, and luciferase expression reporter assays in KP4 cells under 2D and 3D conditions and compared the changes in the expression levels of signaling proteins. Phosphokinase arrays showed increased tyrosine phosphorylation of several signaling proteins, including p38, ERK, EGFR, MSK, Akt, TOR, CREB, HSP-27, STAT2, STAT5α, Hck, Chk-2, c-Jun, RSK1 / 2 / 3, eNOS, p27, and PLC-γ1, in KP4 spheroids compared to KP4 cells cultured in 2D, suggesting a substantial "rewiring" of signaling pathways in 3D conditions (Figures 2 and 3). In KP4 monolayer cultures, MEK inhibition downregulated ERK, RSK, and PLC-γ1 phosphorylation and increased activation of STAT family proteins and Akt (Figure 3). In contrast, KP4 spheroids showed reduced activation of ERK, RSK, and PLC-γ1 as well as Akt and STAT family proteins upon MEK inhibition. MEK inhibition only induced activation of c-Jun in KP4 spheroids.

[0142] qRT-PCR analysis of the expression of mRNAs corresponding to protein kinases in KP4 monolayer and spheroid cultures demonstrated elevated expression in KP4 spheroids for several RTKs, particularly for FGFR3, EPHA1, EPHB6, and INSR (Figure 4). MEK inhibition caused downregulation of most of these RTKs in both KP4 monolayers and spheroids. However, expression of PDGFRα and PDGFRβ was significantly upregulated in KP4 monolayer cultures upon cobimetinib treatment. In contrast, expression of EPHA1 and EPHB1 was selectively elevated in KP4 spheroids upon MEK inhibition (Figure 4). Taken together, these findings reveal a drug response profile specific to 3D culture conditions for PDAC-derived cells that may contribute to the differential sensitivity to drug treatment observed compared to that seen in standard 2D conditions.

[0143] Further evaluation of changes in transcription factor pathway activation upon cobimetinib treatment using a large panel of luciferase reporter assays revealed that KP4 monolayer cultures exhibited increased activation of the following transcription factors: STAT3, c-Myc, GRE, KLF4, ISRE, and GAS (Figure 5). In contrast, KP4 spheroids did not exhibit similar levels of activation of these transcription factors. These results imply differential regulation of multiple transcription factors that may contribute to the activation of alternative pro-survival signaling pathways in response to MEK pathway inhibition in monolayer versus spheroid conditions.

[0144] The phosphokinase array and gene expression array results were validated by western blot for p-PDGFRα, p-STAT3, p-Erk, p-S6, and p-RSK upon cobimetinib treatment of KP4 cells, and increased activation levels of p-PDGFRα, p-STAT3, and p-S6 were observed (Figure 6A). Increased p-STAT3 was also reproducibly detected upon cobimetinib treatment in multiple PDAC human cancer cell lines (Figure 6B). Importantly, increased secretion of IL-6 ligand, which can promote STAT3 activation, was also observed in multiple PDAC cell lines (Figure 7). Consistent with the requirement for STAT3 activation, RNAi knockdown of STAT3 in KP4 and MIA-PACA2 cells induced cell death upon cobimetinib treatment (Figures 8 and 9). Furthermore, in vitro cell invasion assays using multiple PDAC cell lines and KPP-GEMM tumor-derived cell lines demonstrated a decrease in the invasive ability of cancer cells upon MEK inhibition (Figure 10). These results suggest that MEK inhibition as a single agent is not sufficient to cause primary tumor regression, but it may inhibit the invasive ability of cancer cells. Collectively, these results suggest that signaling pathways mediated by PDGFRα, S6, and STAT3 may enable cancer cell survival upon MEK inhibition in pancreatic cancer cells.

[0145] Example 3: Inhibition of PDGFRα, S6, and STAT3 with MEK inhibition effectively promotes apoptosis in PDAC cells. Previous studies have reported that MEK inhibition can result in upregulation and activation of multiple RTKs and the IL6 / JAK / STAT pathway as a "bypass" survival mechanism (Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer, Cell, 2012; 149(2): 307-21. Epub 2012 / 04 / 17, Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J, Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells, Cancer Cell, 2014; 26(2): 207-21, Epub 2014 / 07 / 30, Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, STAT3 mediates resistance to MEK inhibitor through microRNA miR-17, Cancer Research, 2011;71(10):3658-68, Epub 2011 / 03 / 30). However, pancreatic cancer was not involved. The efficacy of the multi-RTK inhibitor ponatinib, which targets both S6 and the JAK2 / STAT3 cascade alone or in combination with cobimetinib, was tested in tumor cell proliferation assays. Cobimetinib treatment promoted STAT3 and S6 activation in PDAC cell lines (Figure 6A), and combination treatment with cobimetinib / ponatinib inhibited activation of PDGFRα, STAT3, S6, ERK1 / 2, and Akt, reduced expression of the pro-survival proteins Bcl-XL, Mcl-1, and survivin, and increased cleaved PARP levels in 2D and 3D cultures (Figures 11, 12, and 13).Although ponatinib has previously been reported to inhibit the kinase activity of ephrin receptors, which could potentially regulate downstream signaling pathways in PDAC cells, cobimetinib / ponatinib combination treatment did not affect the activity of ephrin receptors (EphA2 / 3, EphA2 / 5, and EphA7) in PDAC models (Figure 11).

[0146] Since ponatinib inhibits PDGFRα in addition to FGFR, VEGFR, and ephrin receptors as well as S6 and JAK2 / STAT3 signaling, we further investigated the selective activity of ponatinib by examining the effects of other PDGFRα, S6, and JAK2 inhibitors in combination with cobimetinib. In contrast to the effects of EGFR inhibitor erlotinib or PDGFR inhibitors, downregulation of S6 activation by combination treatment with cobimetinib and S6 inhibitors, rapamycin, or GDC-0980 promoted cell death in KP4 cells (Figures 14, 18, and 19). Simultaneous downregulation of PDGFRα and STAT3 activation after triple combination treatment with PDGFRα inhibitor, crenolanib, JAK2 inhibitor, ruxolitinib, and cobimetinib also inhibited KP4 cell proliferation and caused significant cell death (Figure 15). However, we observed the strongest synergy with cobimetinib / ponatinib treatment, which co-targets RTK, S6, and JAK / STAT and effectively inhibits PDAC cell proliferation (Figures 11, 12, 13, 14, 16, and 17). Treatment of PDAC cell lines with cobimetinib and / or ponatinib did not affect cell viability as single agents, but was synergistic in inhibiting cell proliferation in combination in both 2D and 3D cultures, revealing the cobimetinib / ponatinib combination as a potentially effective therapeutic strategy for PDAC (Figures 12, 16, and 17).

[0147] Example 4: Cobimetinib / ponatinib co-treatment induces tumor regression in mouse models To test the efficacy of the cobimetinib / ponatinib combination in vivo, we performed xenograft studies using KP4 and KPP-GEMM-derived tumor cells. Although both cobimetinib and ponatinib were ineffective as single agents in KP4 xenografts, cotreatment with cobimetinib and ponatinib caused a marked inhibition of tumor growth and increased cell death accompanied by an increase in cleaved caspase 3 (Figures 20 (KP4 cells), 21 and 22). Similar results were obtained with KPP-GEMM-derived cell line xenograft tumors, but we observed a significant delay in tumor growth, as opposed to primarily tumor regression (Figure 20 (KPP cells)). Cobimetinib / ponatinib combination treatment also resulted in 103% TGI (% tumor growth inhibition) in KP4 xenografts and 71% TGI in KPP xenografts (Table 2). Cobimetinib / ponatinib combination treatment caused some concomitant weight loss in mice in the KP4 xenograft study, but not in the KPP-GEMM-derived xenograft study. In the KP4 xenograft study, two mice had to be withdrawn early in the study due to weight loss exceeding 20%. However, no significant weight loss above the acceptable threshold was observed in the remaining mice during the course of combination treatment (Figure 31A). Histopathological analysis, IHC staining, and immunoblotting of implanted tumors confirmed the expected induction of p-PDGFRα, p-STAT3, and pS6 upon cobimetinib treatment, which was significantly downregulated following cotreatment with cobimetinib and ponatinib (Figures 21, 22, 30, and 33). Significantly higher serum levels of PDGFα, PDGFβ, and increased levels of IL-6 were also observed in cobimetinib-treated mice (Figure 23). Cobimetinib / ponatinib co-treatment reduced serum PDGFα and PDGFβ, but not VEGF or FGF levels, highlighting the specific involvement of the PDGFRα pathway by ponatinib in PDAC cancer models (Figures 23 and 32).

[0148] Analysis of myeloid cell compartments within PDAC tumors revealed that F4 / 80+ tumor-associated macrophages (TAMs) were the most predominant myeloid population (Figure 21). Cobimetinib / ponatinib cotreatment markedly reduced the number of TAMs in tumors, induced serum levels of the macrophage inhibitor GCSF, and reduced levels of the macrophage activating factors GM-CSF and MCSF (Figures 22 and 23). These findings indicate that cobimetinib / ponatinib cotreatment is effective in abrogating both tumor and myeloid cell populations by targeting the PDGFRα pathway in addition to downstream MEK, S6, and STAT3 survival pathways. Furthermore, the findings suggest that this combination treatment may promote tumor regression. [Table 2]

[0149] Example 5: Differential activation of Erk and STAT3 in liver metastases of PDAC patients To investigate the potential clinical relevance of these findings, we performed IHC analysis of 76 human PDAC tissue samples and 4 liver metastases for p-Erk and p-STAT3. Erk was activated in 13% of PDAC tissue samples (10 / 76), mainly in patients with stage I and II malignancies, STAT3 activation was observed in 26% of samples (20 / 76), and 6.5% of samples (5 / 76) showed both activated Erk and STAT3, mainly in stage I malignancies (Figures 24 and 25). Furthermore, 50% of liver metastases showed Erk activation (2 / 4), and STAT3 activation was found in 25% of samples (1 / 4) (Figures 24 and 25). Furthermore, gene expression analysis further revealed that PDAC tumors from human patients express increased levels of the RTKs PDGFRα, PDGFRβ, and IL6-R compared to normal tissues (Figure 26, Table 3). [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5]

[0150] The data in Table 3 suggest that PDAC tumors may be driven by PDGFR, IL-6, and STAT3 signaling, and that these pathways may limit the response to MEK pathway inhibition. These findings also indicate that the MEK pathway may play an important role in the survival of tumor cells in liver metastases that do not switch to the STAT3-mediated survival cascade upon metastasis in human pancreatic cancer patients.

[0151] All technical and scientific terms used herein have the same meaning. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for.

[0152] Throughout this specification and the claims, the words "comprise", "comprises" and "comprising" are used in their non-exclusive sense, unless the context otherwise requires. It is understood that the embodiments described herein include embodiments that "consist of" and / or "consist essentially of".

[0153] As used herein, the term "about" when referring to a value is meant to encompass variations from a particular amount, in some embodiments, ±50%, in some embodiments, ±20%, in some embodiments, ±10%, in some embodiments, ±5%, in some embodiments, ±1%, in some embodiments, ±0.5%, and in some embodiments, ±0.1%, as such variations are appropriate for practicing the disclosed methods or using the disclosed compositions.

[0154] When a range of values ​​is provided, unless the context clearly dictates otherwise, each intervening value between the upper and lower limits of that range, and at any other stated or intervening value within that stated range, is included to the tenth of the unit of the lower limit. The upper and lower limits of these smaller ranges that may be independently included in smaller ranges are also included, subject to any specifically excluded limits in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included.

[0155] Many modifications and other embodiments of what is described herein will come to mind to one skilled in the art to which this subject pertains having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. It is to be understood, therefore, that the subject is not to be limited to the specific embodiments disclosed, and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

Claims

1. 1. A combination pharmaceutical product for treating pancreatic cancer in a subject in need of such treatment, comprising a therapeutically effective amount of a combination of active agents, said combination comprising cobimetinib, or a pharmaceutically acceptable salt thereof, and ponatinib, or a pharmaceutically acceptable salt thereof, wherein the cobimetinib, or a pharmaceutically acceptable salt thereof, is present in an amount of 45 mg to 75 mg, and the ponatinib, or a pharmaceutically acceptable salt thereof, is present in an amount of 30 mg to 60 mg.

2. The combination drug of claim 1 , wherein the pancreatic cancer is an endocrine cancer.

3. The combination drug of claim 1 , wherein the pancreatic cancer is an exocrine pancreatic cancer.

4. 4. The combination pharmaceutical of claim 3, wherein the pancreatic cancer is selected from the group consisting of adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma, mucinous carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, hepatoid adenocarcinoma, intraductal papillary mucinous neoplasm, mucinous cystic neoplasm, pancreatoblastoma, serous cystadenoma, signet ring cell carcinoma, solid pseudopapillary tumor, ductal carcinoma, and undifferentiated carcinoma.

5. The combination drug of claim 4, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

6. The pharmaceutical combination of claim 1 , wherein the combination is synergistic.

7. The pharmaceutical combination of claim 1, wherein cobimetinib and ponatinib are administered sequentially.

8. The pharmaceutical combination of claim 1, wherein cobimetinib and ponatinib are administered simultaneously.

9. The combination pharmaceutical of claim 1 , wherein cobimetinib and ponatinib are administered as a combined formulation.

10. The pharmaceutical combination of claim 1 , wherein said amount is administered once daily.

11. 1. A combination pharmaceutical for treating pancreatic cancer in a subject in need thereof, comprising: a) cobimetinib, or a pharmaceutically acceptable salt thereof; and b) ponatinib, or a pharmaceutically acceptable salt thereof.

12. 1. A pharmaceutical composition for the treatment of pancreatic cancer comprising an effective amount of a combination of cobimetinib or a pharma- ceutically acceptable salt thereof and ponatinib or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient, wherein the cobimetinib or a pharma- ceutically acceptable salt thereof is present in an amount of 45 mg to 75 mg, and the ponatinib or a pharma- ceutically acceptable salt thereof is present in an amount of 30 mg to 60 mg.

13. A kit for treating pancreatic cancer comprising cobimetinib or a pharma- ceutically acceptable salt thereof, ponatinib or a pharma- ceutically acceptable salt thereof, a container, and a package insert or label, wherein the cobimetinib or a pharma- ceutically acceptable salt thereof is present in an amount of 45 mg to 75 mg, and the ponatinib or a pharma- ceutically acceptable salt thereof is present in an amount of 30 mg to 60 mg.

14. 12. The pharmaceutical combination of claim 11, wherein the cobimetinib is administered at a dose of 1 mg / kg to 50 mg / kg and the ponatinib is administered at a dose of 1 mg / kg to 50 mg / kg.

15. 15. The pharmaceutical combination of claim 14, wherein the cobimetinib is administered at a dose of 1 mg / kg to 10 mg / kg and the ponatinib is administered at a dose of 10 mg / kg to 40 mg / kg.